Special Issue "Vaccines for Patients With Immunodeficiencies and Their Efficacy: An Overview in Pandemic Era"
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: closed (31 January 2023) | Viewed by 11650
Interests: innate immunity and inflammation in autoimmune diseases and cancer
Immunodeficiency disorders (ID) can be broadly classified into primary (genetic disorders that impair the immune system) and, secondary (e.g. HIV, lymphoma, drugs) disorders with different levels of infection susceptibility. Indeed, without a functional immune response, immunodeficiency patients risk to be not adequately immunized. For this reason, primary care clinicians usually have concerns regarding safety and/or efficacy and appropriate use of vaccination. Vulnerable patients are more than expected: most of them are pediatric patients or subjects treated with corticosteroid, chemotherapy, antimetabolite treatment, anti-CD20 or they have undergone an organ transplant.
The present Special Issue is devoted to gathering the current information about the types of vaccines in use for Immunocompromised patients until the latest use for SARS-CoV2 infection. Moreover, the Special Issue will focus on vaccines effectiveness considering the different types of defects of the immune response and the current approaches to vaccine efficacy forecasting based on machine learning and mathematical model. Finally, regarding the specificity of immunoassay or in immune-phenotyping investigations, it is important to exam which are the current techniques used to detect adequate immunization in these patients for example the analysis of the memory cells or the titration of immunoglobulin (in those patients whom this approach is applicable) or specific markers of immunogenicity.
Now more than ever, vaccination is the unique way to fight the current pandemic infection but, in general, as scientists specializing in clinical immunology, we observed the urgent need to make clear which are the available vaccines for Immunocompromised patients and the specific recommendations on the vaccination strategies for the vulnerable patients depending on the defects in their the immune response.
We are pleased to invite you to submit a contribution to this Special Issue
- The aim is to have a comprehensive analysis of types of vaccines in current use for Immunocompromised patients until the latest use for SARS-CoV2 infection. Taking in consideration the advanced technologies rapidly expanded over the last years in computational analysis or the predictive models and in vitro immunoassay, this special issue wants to explore the effectiveness of the vaccines to optimize the development of safety and tolerable protocols for vulnerable patients.
- This Special Issue will collect the following article types: Original research articles, Clinical Case reports, Reviews and Perspective analysis. The Research areas may include the following subjects (but not limited to): Clinical Immunology, Mathematical modeling, Machine learning analysis, Cellular Immunology. Allergology, Virology.
We look forward to receiving your contributions.
Prof. Dr. Lo Presti Elena
Dr. Trizzino Antonino
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- primary immunodeficiency
- secondary immunodeficiency
- vaccination strategies
- machine learning
- predictive biomarkers
- predictive model